Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 15 Paraganglioma 4 Meningioma 4 Carcinoma, Neuroendocrine 4 Pheochromocytoma 3 Gastro-enteropancreatic neuroendocrine tumor 2 Carcinoma, Medullary 2 Carcinoid Tumor 2 Somatostatinoma 1 Serotonin Syndrome 1 Prostatic Neoplasms 1 Pituitary Neoplasms 1 Parathyroid Neoplasms 1 Neuroblastoma 1 Neoplasms 1 Metastatic Digestive System Neuroendocrine Tumor G1 1 Hypertension 1 Disease Progression 1 Carcinoma, Merkel Cell 1 Carcinoid Heart Disease 1 Breast Neoplasms 1 Advanced Lung Neuroendocrine Tumor 1 Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 34 Etoposide 25 Doxorubicin 20 Carboplatin 20 Vincristine 19 Isotretinoin 19 Topotecan 17 Temozolomide 17 Irinotecan 16 Filgrastim 16 Melphalan 15 Cisplatin 15 sargramostim 14 Radiotherapy 14 Granulocyte-Macrophage Colony-Stimulating Factor 13 3-Iodobenzylguanidine 12 dinutuximab 11 Peripheral Blood Stem Cell Transplantation 11 naxitamab 9 Thiotepa 9 Magnetic Resonance Spectroscopy 9 humanized 3F8 anti-GD2 monoclonal antibody 7 Granulocyte Colony-Stimulating Factor 7 Busulfan 7 X-Rays 6 Specimen Handling 6 Phantoms, Imaging 6 Ifosfamide 6 Antilymphocyte Serum 6 fludarabine phosphate 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neuroblastoma × lutetium Lu 177 dotatate × Clear all

NCT04903899 2025-02-11

LuDO-N

Karolinska University Hospital

Phase 2 Recruiting

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡